Delivering full-viral RNA blueprints that safely turn cancer’s biology against itself
Our Breakthrough
A Full-Viral Blueprint
ViVac’s proprietary platform encodes the entire viral blueprint — not just fragments of genetic information — within a safe, self-limiting RNA replicon.
Once delivered into tumor cells using precision-engineered lipid nanoparticles (LNPs), the RNA replicates only once, creating a controlled, localized immune response that destroys cancer cells from within — without spreading beyond the tumor.
It’s the power of a virus, reprogrammed for safety.
ViVac’s platform begins with synthetic RNA blueprints, engineered through synthetic biology to include both viral and immunostimulatory components. These are encapsulated in next-generation lipid nanoparticles, designed to precisely target tumor sites. Once inside cancer cells, the RNA replicates only once, triggering a safe, localized antiviral-like response that destroys tumor cells and reshapes the surrounding microenvironment. This process activates both T-cell (intracellular) and antibody (extracellular) responses, achieving potent, durable, and localized cancer immunotherapy — with RNA-level precision.
Why it Matters
Checkpoint inhibitors, oncolytic viruses, and mRNA vaccines have transformed oncology, but most patients still don’t respond.
Existing therapies are limited by toxicity, poor tumor penetration, or a narrow immune focus.
ViVac was created to overcome those limits — combining viral potency with RNA-level safety.
How It Started
ViVac’s journey began with the poliovirus — one of nature’s most powerful immune activators. By decoding its full viral blueprint and reengineering it through synthetic biology, our scientists transformed a once-feared virus into a safe, self-limiting RNA platform. What started as a vaccine concept evolved into a breakthrough technology capable of reprogramming the immune system to recognize and destroy cancer.
Why It Works
Cancer and viruses share a key vulnerability — both can be identified and eliminated by the immune system when properly activated. ViVac’s RNA platform harnesses this principle by mimicking a viral infection inside the tumor, provoking a strong yet controlled immune response. The result is targeted tumor destruction and long-lasting immune memory, without the risks of live viral therapies.
